Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 47103J105 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Point72 Asset Management, L.P.
13G/A
Amendment 1
|
3.3% |
8/14/2026
Event 6/30/2026
|
|
| Point72 Asset Management, L.P. | 3.3% | ||
| Point72 Capital Advisors, Inc. | 3.3% | ||
| Steven A. Cohen | 3.3% | ||
| Janus Henderson Group Ltd. 13G/A Amendment 6 | 0.3% |
8/13/2026
Event 6/30/2026
|
|
| BlackRock, Inc. 13G/A Amendment 1 | 6.7% |
7/28/2026
Event 6/30/2026
|
|
| Janus Henderson Group PLC 13G/A Amendment 5 | 6.9% |
5/15/2026
Event 3/31/2026
|
|
| State Street Corp 13G | 4.1% |
5/12/2026
Event 3/31/2026
|
|
|
FMR LLC
13G/A
Amendment 5
|
4.2% |
5/6/2026
Event 3/31/2026
|
|
| FMR LLC | 4.2% | ||
| Abigail P. Johnson | 4.2% | ||
|
Point72 Asset Management, L.P.
13G
|
5.0% |
4/29/2026
Event 4/28/2026
|
|
| Point72 Asset Management, L.P. | 5.0% | ||
| Point72 Capital Advisors, Inc. | 5.0% | ||
| Steven A. Cohen | 5.0% | ||
|
Point72 Asset Management, L.P.
13G
|
5.0% |
4/29/2026
Event 4/28/2026
|
|
| Point72 Asset Management, L.P. | 5.0% | ||
| Point72 Capital Advisors, Inc. | 5.0% | ||
| Steven A. Cohen | 5.0% | ||
| Janus Henderson Group PLC 13G/A Amendment 4 | 8.9% |
2/17/2026
Event 12/31/2025
|
|
| State Street Corp 13G | 6.4% |
2/9/2026
Event 12/31/2025
|
|
|
Prosight Management, LP
13G
|
5.3% |
2/6/2026
Event 2/3/2026
|
|
| Prosight Management, LP | 5.2% | ||
| Prosight Fund, LP | 0.2% | ||
| Prosight Plus Fund, LP | 1.1% | ||
| Prosight Partners, LLC | 5.2% | ||
| W. Lawrence Hawkins | 5.3% | ||
|
FMR LLC
13G/A
Amendment 4
|
5.8% |
1/8/2026
Event 12/31/2025
|
|
| FMR LLC | 5.8% | ||
| Abigail P. Johnson | 5.8% | ||
| Janus Henderson Group PLC 13G/A Amendment 3 | 10.0% |
11/7/2025
Event 10/31/2025
|
|
| Janus Henderson Group PLC 13G/A Amendment 2 | 7.5% |
8/14/2025
Event 6/30/2025
|
|
|
Paradigm Biocapital Advisors LP
13G/A
Amendment 2
|
4.9% |
8/14/2025
Event 6/30/2025
|
|
| Paradigm BioCapital Advisors LP | 4.9% | ||
| Paradigm BioCapital Advisors GP LLC | 4.9% | ||
| Senai Asefaw, M.D. | 4.9% | ||
| Paradigm BioCapital International Fund Ltd. | 4.4% | ||
|
Adage Capital Management, L.P.
13G/A
Amendment 1
|
4.3% |
8/12/2025
Event 6/30/2025
|
|
| Adage Capital Management, L.P. | 4.3% | ||
| Robert Atchinson | 4.3% | ||
| Phillip Gross | 4.3% | ||
| BlackRock, Inc. 13G | 5.7% |
7/17/2025
Event 6/30/2025
|
|
| Janus Henderson Group PLC 13G/A Amendment 1 | 7.8% |
5/14/2025
Event 3/31/2025
|
|
|
RA Capital Management, L.P.
13D/A
Amendment 4
|
19.9% |
3/10/2025
Event 3/6/2025
|
|
| RA Capital Management, L.P. | 19.9% | ||
| Peter Kolchinsky | 19.9% | ||
| Rajeev Shah | 19.9% | ||
| RA Capital Healthcare Fund, L.P. | 18.2% | ||
| Janus Henderson Group PLC 13G | 6.1% |
2/14/2025
Event 12/31/2024
|
|
|
Paradigm Biocapital Advisors LP
13G/A
Amendment 1
|
6.0% |
2/14/2025
Event 12/31/2024
|
|
| Paradigm BioCapital Advisors LP | 6.0% | ||
| Paradigm BioCapital Advisors GP LLC | 6.0% | ||
| Senai Asefaw, M.D. | 6.0% | ||
| Paradigm BioCapital International Fund Ltd. | 5.2% | ||
|
Adage Capital Management, L.P.
13G
|
5.3% |
2/12/2025
Event 12/31/2024
|
|
| Adage Capital Management, L.P. | 5.3% | ||
| Robert Atchinson | 5.3% | ||
| Phillip Gross | 5.3% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 5 | 90.2 k | $1.56 M |
| 2026 Q2 | 210 | 62.4 M | $997 M |
| 2026 Q1 | 203 | 59.6 M | $828 M |
| 2025 Q4 | 194 | 62.2 M | $860 M |
| 2025 Q3 | 186 | 65.4 M | $1.60 B |
| 2025 Q2 | 189 | 65.8 M | $1.52 B |
| 2025 Q1 | 196 | 66.5 M | $1.81 B |
| 2024 Q4 | 234 | 64.1 M | $3.43 B |
| 2024 Q3 | 171 | 45.6 M | $2.07 B |
| 2024 Q2 | 170 | 46.3 M | $1.94 B |
| 2024 Q1 | 132 | 43.1 M | $1.62 B |
| 2023 Q4 | 72 | 33.6 M | $361 M |
| 2023 Q3 | 62 | 35.1 M | $354 M |
| 2023 Q2 | 57 | 30.5 M | $362 M |
| 2023 Q1 | 51 | 30.5 M | $370 M |
| 2022 Q4 | 54 | 29.2 M | $385 M |
| 2022 Q3 | 51 | 31.5 M | $427 M |
| 2022 Q2 | 45 | 28.9 M | $353 M |
| 2022 Q1 | 48 | 28.4 M | $407 M |
| 2021 Q4 | 47 | 27.5 M | $542 M |
| 2021 Q3 | 46 | 26.5 M | $571 M |
| 2021 Q2 | 31 | 24.7 M | $614 M |